Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Esperion sold by Pfizer; closes $55.8mm Series A round

03 May 2013

Executive Summary

After acquiring Esperion Therapeutics (cardiovascular and metabolic compounds) in 2003 for $1.25bn, Pfizer has now decided to spin off the company to a syndicate of investors. Esperion has simultaneously closed a tranched $22.75mm Series A venture round co-led by new investors Aisling Capital and Domain Associates, and returning backer Alta Partners, all of which contribute one member to the company's board. Arboretum Ventures also participated.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By